Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Oxford Nanopore appoints Dr John Milton and Clive G. Brown

Abstract:
Oxford Nanopore Technologies Ltd ("Oxford Nanopore") today announces the appointment of Dr John Milton as Director of Nanopore Chemistry and Clive G. Brown as Director of Bioinformatics and IT.

Oxford Nanopore appoints Dr John Milton and Clive G. Brown

Oxford, UK | Posted on June 10th, 2008

Oxford Nanopore is developing nanopore technology into a molecular detection and analysis platform with a broad range of applications including DNA sequencing. Dr Milton and Clive Brown bring outstanding, relevant experience to their roles at the Company.

Dr Milton was previously Senior Director of Research at Solexa, a Cambridge University spin-out. At Solexa he was principal architect of the sequencing-by-synthesis chemistry that formed the basis of the Genome Analyzer, now a leading second generation DNA sequencing technology. His previous experience includes roles at GlaxoWellcome and Xenova.

Clive G. Brown joins Oxford Nanopore from the Wellcome Trust Sanger Institute (WTSI), Cambridge, UK. At the WTSI he played a key role in the adoption, operation and development of 'next generation' DNA sequencing platforms. WTSI has recently submitted hundreds of Gigabases of high quality data to the 1000 genomes project. Prior to this he was Director of Computational Biology & IT at Solexa.

"We are delighted to welcome John Milton and Clive Brown to our team," said Dr Gordon Sanghera, CEO of Oxford Nanopore. "The appointment of two senior executives with an exceptional track record in sequencing technology reflects the acceleration of our programme to deliver a nanopore-based, label-free, single molecule sequencing system. John and Clive bring not only great technical expertise but also a deep understanding of sequencing applications. This knowledge will help us to develop a sequencing system that truly meets the needs of researchers."

####

About Oxford Nanopore Technologies Ltd
Oxford Nanopore is developing nanopore technology, a revolutionary method of molecular detection and analysis with potential for DNA sequencing, diagnostics, drug development and defence applications. The company was founded on the science of Professor Hagan Bayley of the University of Oxford.

The Company's BASE™ technology is a system for DNA sequencing that employs nanopores to process, identify and record DNA bases in sequence. In contrast to current sequencing technologies, nanopores offer a potential method of directly sequencing DNA at single molecule resolution. This removes the need for amplification or labelling, and allows detection from an electrical signal rather than by fluorescence-based CCD imaging. In order to make a breakthrough in speed and cost, other competing technologies require step changes in optics, computation, and CCD camera technologies. Nanopores provide an alternative path to a step-change in the power and cost of DNA sequencing.

Recent interest in the “race for the $1000 genome" illustrates the needs for a sequencing technology that is affordable and powerful enough to enable an exponential increase in research and understanding of the genome. This knowledge will enable a new era in medicine, agriculture, energy, biodiversity, evolutionary biology, genealogy and many other fields.

The nanopore molecular detection system is powerful and versatile beyond its DNA sequencing potential. It can be adapted to detect a wide range of molecules, including other nucleic acids, proteins, small organic molecules and ionic species.

John Milton PhD, Director of Nanopore Chemistry

John followed his PhD in Organic Chemistry with positions at GlaxoWellcome and Xenova, where he specialised in designing new chemical systems that interact with the biological machinery of genetic processing. During his pharmaceutical career he delivered a number of novel therapeutic molecules into the clinic in the areas of HIV, virology, cancer and cancer related multidrug resistance. This included the HIV therapy Lamivudine (Epivir).

In 2001, John joined the Cambridge University spin-out Solexa, where he was principal architect of the novel sequencing-by-synthesis chemistry. As Senior Director of Research, he built and managed a team of 50 scientists, and took the technology through research, scale up, production, manufacturing and productisation for eventual commercial launch of the Genome Analyzer system in late 2006. From seed funding Solexa successfully raised over $150m before eventual sale to Illumina Inc for over $600m in early 2007.

Most recently, John has been closely involved with a number of biotech startups, looking to exploit the vast wealth of new human sequence data in the medical diagnostics field.

Clive G. Brown, Director of Bioinformatics & IT

Clive joined Oxford Nanopore Technologies from the Wellcome Trust Sanger Institute (Cambridge, UK) where he played a key role in the adoption and exploitation of 'next generation' DNA sequencing platforms, culminating in the submission of hundreds of Gigabases of high quality data to the 1000 genomes project.

Prior to this he was Director of Computational Biology & IT at Solexa, where he was integral to the development of the Genome Analyzer (GA). Clive's team built Solexa's high-performance computing infrastructure and supported all of the breakthrough science behind the GA's development. The group also provided the software tools, core algorithms, data and relationship building that enabled subsequent product adoption.

Clive has held various management and consulting positions at GlaxoWellcome, Oxford Glycosciences and other EU- and US-based organisations, where he has worked at the interface between computing and science, ranging from genetics to proteomics. He has also been responsible for several successful commercial data products and holds degrees in Genetics and Computational Biology from the University of York.

For more information, please click here

Contacts:
Dr Gordon Sanghera, CEO
Zoe McDougall, Communications
+44 (0)870 486 1966

Copyright © Oxford Nanopore Technologies Ltd

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

MRI, on a molecular scale: Researchers develop system that could one day peer into the atomic structure of individual molecules April 20th, 2014

Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014

Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

Announcements

MRI, on a molecular scale: Researchers develop system that could one day peer into the atomic structure of individual molecules April 20th, 2014

Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014

Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014

Innovative strategy to facilitate organ repair April 18th, 2014

Tools

MRI, on a molecular scale: Researchers develop system that could one day peer into the atomic structure of individual molecules April 20th, 2014

Oxford Instruments Asylum Research Introduces the MFP-3D InfinityTM AFM Featuring Powerful New Capabilities and Stunning High Performance April 18th, 2014

More effective kidney stone treatment, from the macroscopic to the nanoscale April 17th, 2014

Aerotech X-Y ball-screw stage for economical high performance Planar positioning April 16th, 2014

Appointments/Promotions/New hires/Resignations/Deaths

Nanobiotix Appoints Thierry Otin as Head of Manufacturing and Supply April 15th, 2014

Industry Veteran Fergus Clarke Joins Picodeon as CEO: Appointment comes as Picodeon prepares for growth April 8th, 2014

Peter B. Littlewood appointed Director of Argonne National Laboratory March 26th, 2014

Global 450 consortium announces new general manager of internal operations: TSMC’s Cheng-Chung Chien Receives Unanimous Support, Brings History of Innovation and Efficiency to Global Consortium of Companies Driving Industry Transition to 450mm Wafer Technology March 26th, 2014

Nanobiotechnology

Targeting cancer with a triple threat: MIT chemists design nanoparticles that can deliver three cancer drugs at a time April 15th, 2014

Biologists Develop Nanosensors to Visualize Movements and Distribution of Plant Stress Hormone April 15th, 2014

In latest generation of tiny biosensors, size isn't everything: UCLA researchers overturn conventional wisdom on nanowire-based diagnostic devices April 11th, 2014

Virus structure inspires novel understanding of onion-like carbon nanoparticles April 10th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE